ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Horizons Psychedelic Stock Index ETF

Horizons Psychedelic Stock Index ETF (PSYK)

6,55
0,00
(0,00%)
Fermé 26 Décembre 10:00PM
Données en temps réel

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

Dernier
6,55
Prix Achat
6,55
Prix Vente
6,55
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Clôture Veille
6,55
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume moyen (3 m)
-
Volume financier
-
VWAP
-

PSYK Dernières nouvelles

Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose

VANCOUVER, British Columbia, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...

Algernon Pharmaceuticals Announces Small Cell Lung Cancer Ifenprodil Research Program and Appoints Dr. William North as Lead Consultant

VANCOUVER, British Columbia, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...

Algernon Pharmaceuticals Announces Exclusive Licensing Agreement with Dartmouth College

VANCOUVER, British Columbia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...

Algernon Pharmaceuticals Announces 70% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

VANCOUVER, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) (the “Company” or “Algernon”), a clinical stage...

Algernon Pharmaceuticals Announces it Will Not Advance Ifenprodil into Phase 3 Trial for COVID-19

VANCOUVER, British Columbia, July 06, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...

Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021

VANCOUVER, British Columbia, June 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that...

Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical Research Program with Ifenprodil

VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has initiated a...

Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke

VANCOUVER, British Columbia, May 27, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to highlight an...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000SP
40000000SP
120000000SP
260000000SP
520000000SP
1560000000SP
2600000000SP
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock